Turnstone Biologics has formed a broad strategic alliance with Moffitt Cancer Center for advancing the development of next-generation tumour-infiltrating lymphocyte (TIL) therapies for solid tumours.
UK-based Mogrify has collaborated with Astellas Pharma to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss.
Regeneron Pharmaceuticals has completed the purchase of Sanofi's stake in cancer drug Libtayo (cemiplimab).
Digital health start-up Mesh Bio has collaborated with drug discovery company MultiOmic Health to use artificial intelligence (AI) for developing precision medicines and diagnostics for chronic metabolic disease.
Generian Pharmaceuticals has signed a collaboration and exclusive license agreement with Astellas Pharma’s wholly owned subsidiary Mitobridge for the research and development of new small molecules for undruggable therapeutic targets.
Palleon Pharmaceuticals and Shanghai Henlius Biotech have entered into a strategic collaboration for the development and commercialisation of two bifunctional sialidase therapies.
ImmunoGen and Oxford BioTherapeutics (OBT) have entered into a multi-year research collaboration to develop new antibody-drug conjugates (ADCs) to treat cancers.
Olema Pharmaceuticals (Olema Oncology) has announced an exclusive global license agreement with Aurigene Discovery Technologies to discover, develop, and commercialise new cancer therapies.
Biotech company Upstream Bio has raised $200m in Series A financing round to advance development of new therapeutics for allergic and inflammatory diseases.
Sapience Therapeutics has raised $41m in a Series B funding round to advance the pipeline of peptide therapeutics targeting protein-protein interactions.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.